探討硫酸鎂治療小兒喘息性疾病的臨床效果及安全性

趙樹峰

[摘要] 目的 探討分析硫酸鎂治療小兒喘息性疾病的臨床效果及安全性。方法 回顧性分析于2016年1月—2017年12月期間在該院治療的小兒喘息性疾病患兒120例作為該次研究對象，按照患兒的不同治療方法均分為兩組，對照組和研究組患兒各60例。對照組患兒行常規(guī)治療，研究組患兒則在常規(guī)治療基礎(chǔ)之上行硫酸鎂治療。對比分析兩組患兒的臨床治療療效以及各項(xiàng)觀察指標(biāo)和并發(fā)癥發(fā)生率相較。 結(jié)果 通過對兩組患兒行不同治療方法，研究組患兒的臨床治療有效率相較對照組患兒明顯較高，分別為95.00%與85.00%，兩組差異有統(tǒng)計(jì)學(xué)意義（χ2=8.924，P<0.05）;研究組患兒的肺部濕啰音、喘息以及咳嗽等癥狀的消失時(shí)間，以及平時(shí)的住院時(shí)長相較對照組明顯較短，兩組差異有統(tǒng)計(jì)學(xué)意義（χ2=5.617，P<0.05）;且研究組患兒的臨床并發(fā)癥發(fā)生率相較對照組明顯較少，分別為3.33%和10.00%，兩組差異有統(tǒng)計(jì)學(xué)意義（χ2=5.617，P<0.05）。 結(jié)論 通過對小兒喘息性疾病患兒，行硫酸鎂藥物治療可以取得顯著的治療療效，且能夠有效縮短患兒身體病癥的存在時(shí)間，提升患兒的身體康復(fù)速率，藥物起效時(shí)間相對較快，且無毒副作用減少患兒身體不良反應(yīng)發(fā)生率，具有臨床推廣意義。

[關(guān)鍵詞] 硫酸鎂;小兒喘息性疾病;安全性

[中圖分類號] R725.6? ? ? ? ? [文獻(xiàn)標(biāo)識碼] A? ? ? ? ? [文章編號] 1674-0742（2019）05（a）-0112-03

[Abstract] Objective To analyze the clinical effect and safety of magnesium sulfate in the treatment of children with wheezing disease. Methods A retrospective analysis of 120 children with pediatric wheezing disease treated in our hospital from January 2016 to December 2017 was conducted. The treatment groups were divided into two groups according to the different treatment methods of the children， with 60 children in each group. The control group received routine treatment， and the study group was treated with conventional magnesium sulfate on the basis of conventional treatment. The clinical treatment efficacy of the two groups of children and the comparison of the observed indicators and the complication rate were compared. Results The clinical treatment efficiency of the children in the study group （95.00%） was significantly higher than that of the control group （85.00%）. There were statistically significant differences between the two groups （χ2=8.924， P<0.05）. The disappearance time of symptoms such as wetness， wheezing and cough in the lungs of the study group， and the usual length of hospitalization were significantly shorter than those in the control group， and there were statistically significant differences between the two groups （χ2=5.617， P<0.05）. The incidence of clinical complications in the study group （3.33%） was significantly lower than that in the control group （10.00%）. The difference between the two groups was statistically significant （χ2=5.617， P<0.05）. Conclusion Children with sexually transmitted diseases can achieve significant therapeutic effects by taking magnesium sulphate medication， which can effectively shorten the time of physical condition of the child， improve the rate of physical recovery of the child. And the drug has a relatively fast onset time without toxic side effects. The incidence of adverse reactions in children has clinical significance.